AI is an opportunity, not a threat, for PTC's business model, and growth in its key metric is set to rebound in the near future. The stock's valuation hasn't been this cheap in a decade.
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.
Skandinaviska Enskilda Banken AB publ lifted its stake in PTC Inc. (NASDAQ: PTC) by 8.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 90,828 shares of the technology company's stock after purchasing an additional 6,724 shares during the quarter. Skandinaviska
WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review.
Addresses performance, data consistency, and workflow challenges that slow product development and impact downstream teams Enables faster, more collaborative product execution with a cloud-based PLM solution built to support future growth BOSTON, Feb. 12, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that SPG Company, a global leader in licensed product design, development, manufacturing, and distribution, has selected PTC's FlexPLM® retail product lifecycle management (PLM) solution to modernize and support its end-to-end product lifecycle operations. With FlexPLM, SPG will replace its legacy PLM system with a scalable, cloud-based platform designed to support faster development cycles and more consistent product data.
Drake and Associates LLC purchased a new position in shares of PTC Inc. (NASDAQ: PTC) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,647 shares of the technology company's stock, valued at approximately $1,833,000. Other hedge funds have also made
Code Rebel (OTCMKTS:CDRBQ - Get Free Report) and PTC (NASDAQ: PTC - Get Free Report) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability. Institutional and Insider Ownership 95.1% of PTC
PTC (NASDAQ: PTC) executives said the company delivered a "solid" start to fiscal 2026, pointing to steady annual recurring revenue (ARR) growth, expanding free cash flow, and what they described as improving demand capture tied to its "Intelligent Product Lifecycle" strategy. On the company's fiscal first-quarter earnings call, CEO Neil Barua said PTC grew constant-currency ARR
PTC's Q1 FY26 EPS surges 75% Y/Y to $1.92 and revenues jump 21%, beating guidance and consensus while IPL strategy and large deals gain traction.
WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m.
